May 13, 2024 7:20am

1 net income of 24 releases (of 35 covered) so far, mostly Q1 losses, missed EPS and revenue expectations stunted by G&A increases

Earnings: Voyager Therapeutics (VYGR)

Financing: Harvard Apparatus RT (OTCQB: HRGN closed @ $2.32) On April 15, 2024, <SEC filing> entered into Securities Purchase Agreements with investors pursuant agreeing to purchase in a private placement (PP) an aggregate of 367,767 shares of common stock for a purchase price of $1.5 million and a unit price of $4.03. More and more outstanding shares as losses inflate exponentially since spinout in 2009 with no clinical result to date or anticipated short or near-term. Also, what valuation model would even/ever justify this PP pricing?

Pre-open Indications: 2 Positive and 3 Negative Indications

Markets await both next week's producer price index and the consumer price index for signs that U.S. inflation has resumed its downward trend toward the Fed's 2% target rate.

Never leave an investor uninformed

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RM

 

Monday: The pre-open Dow futures are UP +0.09% or (+35 points), the S&P futures are UP +0.15% or ( +8 points) as the Nasdaq futures are UP +0.24% or (+43 points)

Stock futures rose slightly Monday, May 13, 2024

European markets were mixed at the start of the new trading week,

Asia-Pacific markets were largely lower as investors assessed China’s stronger-than-expected April inflation data.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday: The Dow closed UP +125.08 points or +0.32%, the S&P closed UP +8.60 points or +0.16% while the Nasdaq closed DOWN -5.40 points or -0.03

Economic Data Docket: New York Fed one-year inflation expectations, April (3% previously)

  • The producer price index (PPI) is due Tuesday, with the consumer price index (CPI) on Wednesday and an update on retail sales.
  • Economists expect that retail sales increased 0.4% in April from the prior month, down from a 0.7% increase seen in March.
  • Initial jobless claims will also be in focus after the weekly data set hit a surprise nine-month high in the first week of May.

 

Friday night’s RegMed Investors (RMi) Closing Bell: “racing to anther bottom. Sentiment is yet again not moving in the right direction” … https://www.regmedinvestors.com/articles/13456

 

Q2/24:  May – 5 positive and 3 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Negative indications:

Friday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed down -$1.23 after Thursday’s +$0.25, Wednesday’s -$0.54, Tuesday’s -$0.94 and last Monday’s -$0.12 with a neutral pre-open indication.

BioLife Solutions (BLFS) closed up +$1.53 with a neutral pre-open indication.

Blueprint Medicine (BPMC) closed down -$1.64 after Thursday’s -$0.44, Wednesday’s +$0.23, Tuesday’s +$2.30 and last Monday’s -$0.94 with a neutral pre-open indication.

Mesoblast (MESO) closed up +$0.19 with a negative -$0.36 or -4.89% pre-open indication.

 

Positive indications:

Friday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$0.90 after Thursday’s -$0.92, Wednesday’s +$2.04, Tuesday’s +$3.11 and last Monday’s -$1.11 with a neutral pre-open indication.

Intellia Therapeutics (NTLA) closed down -$0.40 after Thursday’s +$1.86, Wednesday’s -$0.88, Tuesday’s +$0.16 and last Monday’s +$0.12 with a positive +$0.05 or +0.25% pre-open indication

 

The BOTTOM LINE: Last week, markets had a solid yet data quiet week, with the key indexes moving toward record 52-week highs.

  • But inflation data looms …

 

This week's inflation reports could propel the major indexes to record highs or knock them back toward the 50-day. In the week ahead, a crucial April inflation reading and an update on retail sales will highlight the economic calendar. Initial jobless claims will also be in focus after the weekly data set hit a surprise nine-month high in the first week of May. <Josh Schaefer, Yahoo Finance>

 

Investors must eye-ball earnings results, runways, and forecasts. Missed EPS and revenue indications usually signify the changing landscape of short and near-term prospects and trends.

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

With this in mind, missed estimates reveal a sign of pessimism about sector company's share pricing outlook other than possible pop tarts of clinical results or potential partnership or acquisition actions.

My on-going theses suggests that estimates have a direct relationship with upcoming stock price performance.

Coming date: https://www.regmedinvestors.com/articles/13441

  • Precigen (PGEN) Tuesday, 5/14

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.